Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 530 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR A Cancer Revolution: What the experts think of the new Science... July 25, 2022 Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App September 18, 2021 A new target to slow down ageing and reduce blood cancer... June 29, 2023 Man Who Lost Wife to Breast Cancer Wants to Donate Her... June 5, 2021 Load more HOT NEWS Her Wedding Ceremony Was Interrupted By A Voice In The Back,... Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab... BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... The UK Government’s spending review: Time to invest in the future...
